Navigation Links
New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies

Reinforces Importance of DHA/ARA in Infant Diet

EVANSVILLE, Ind., Sept. 18 /PRNewswire-FirstCall/ -- A recently published study of 4 year olds who had been fed Enfamil LIPIL infant formula exclusively for their first 17 weeks of life has become the longest-term analysis of its kind to demonstrate breastfed-equivalent visual and IQ outcomes among formula- fed infants.(1) The study, which appeared in the journal Early Human Development, was funded by a grant from the National Institutes of Health.

"What this study means for parents is that we now have even longer-term evidence that DHA and ARA supplementation at the levels in Enfamil LIPIL is associated with visual acuity and brain development benefits similar to breast milk," said Deborah Diersen-Schade, Ph.D., a research fellow at Mead Johnson Nutritionals. Previously, brain and eye development outcomes similar to breast milk had been followed in the same group of infants out to 18 months of age.(2, 3)

DHA (docosahexaenoic acid) and ARA (arachidonic acid) are nutrients known as "long-chain polyunsaturated fatty acids (LCPUFA)" that are present in breast milk.

They are critical for development of the eyes, brain and central nervous system. They begin accumulating in the infant's tissues during gestation, especially during the third trimester. Recent evidence suggests that they continue to support the development of visual acuity throughout the first full year of life.(4)

Dr. Diersen-Schade emphasized that the new study addresses two other issues that are important for parents and physicians -- those issues being DHA and ARA levels and control group outcomes.

"The levels of DHA and ARA in Enfamil LIPIL were derived from our evaluation of the levels of both nutrients in human milk worldwide," she said. "The results that Dr. Birch and her colleagues obtained from this analysis as well as earlier positive results from previous studies are based on formulas with DHA at those levels. Researchers who have conducted studies of infant formula that included lower levels have not consistently demonstrated improved outcomes when compared with formula not containing DHA and ARA." (5,6)

Regarding control group outcomes, Diersen-Schade explained that the recent Birch study, which enrolled infants born from 1993 to 1995, also included a control group of infants who received Enfamil with Iron as it was available at the time without DHA and ARA supplementation.

"There were significant differences in visual acuity and verbal IQ scores in the control group versus the breastfed group," she said. "That's important; but what's meaningful is that the similar outcomes for Enfamil LIPIL compared to breast milk were still observable at 4 years of age. Equally interesting, the DHA and ARA group was fed Enfamil LIPIL for only four months; yet their results were similar to infants who were breastfed on average for 10 months."

John Colombo, Ph.D., associate director for cognitive neuroscience and professor of psychology at the University of Kansas, said that the Birch study provides long-awaited data about the links between fatty acids in the infant diet and measures of cognitive function, such as IQ. "Quite simply, these data are the clearest evidence yet that show the beneficial effects of LCPUFA on cognitive and intellectual development - and that LCPUFA should be part of the nutritional regimen in early life," he said. "These results suggest that formulas supplemented with these levels of LCPUFA produce gains in cognitive and intellectual function over formulas without these levels."

About Mead Johnson

Mead Johnson Nutritionals is a world leader in nutrition, dedicated to helping provide infants and children with the best start in life. Mead Johnson Nutritionals is a Bristol-Myers Squibb company.


1. Birch EE et al. Visual acuity and cognitive outcomes at 4 years of age

in a double-blind, randomized trial of long-chain polyunsaturated

fatty-acid supplemented infant formula. Early Hum Dev (2007), doi:


2. Birch EE et al. A randomized controlled trial of early dietary supply

of long-chain polyunsaturated fatty acids and mental development in

term infants. Dev Med Child Neurol (2000); 42:174-81.

3. Hoffman DR, et al. Maturation of visual and mental function in 18-month

old infants receiving dietary long-chain polyunsaturated fatty acids.

FASEB J (2003); 17: A727-A728.

4. Morale SE et al. Duration of long-chain polyunsaturated fatty acids

availability in the diet and visual acuity. Early Hum Dev (2005); 81,


5. Auestad N et al. Visual, cognitive, and language assessments at 39

months: a follow-up study of children fed formulas containing

long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics

(2003); 112: 177-83

6. Scott DT. Formula supplementation with long-chain polyunsaturated fatty

acids: are there developmental benefits? Pediatrics (1998); 102: 59.

(Electronic publication.)

SOURCE Mead Johnson
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):